Učitavanje...

Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer

INTRODUCTION: Erlotinib has prolonged survival in unselected patients with advanced non-small cell lung cancer, whereas sunitinib has yielded promising rates of disease control in previously treated patients. We conducted a dose escalation study of this combination to determine the maximum tolerated...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: O’Mahar, Shannon E., Campbell, Toby C., Hoang, Tien, Seo, Songwon, Kim, KyungMann, Larson, Martha M., Marcotte, Sarah M., LoConte, Noelle K., Traynor, Anne M.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3359645/
https://ncbi.nlm.nih.gov/pubmed/21623267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31820db227
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!